ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test.


ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias, and  advance the development of more targeted treatments.

ADmit Therapeutics is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), which has been granted by Spanish and European grants, and has received private investments from Ship2B, GENESIS Biomed, BStartup10 and other investors since its inception at the end of 2017.

Scroll to Top